IBA : 2024 AGM - Convening Notice Cher Actionnaire, Nous avons l’honneur de vous convoquer à l’Assemblée Générale Ordinaire (l’« AGO ») des actionnaires d’IBA qui se tiendra le mercredi 12 juin 2024 à 10h00, pour délibérer sur l’ordre du jour détaillé ci-joint. L’AGO sera organisée en présentiel au siège de la Société. Une retransmission est également prévue en ligne, accessible sur inscription préalable, mais il ne sera pas possible de voter en ligne. Il s’agit d’une simple retransmission. Les actionnaires sont fortement encouragés à voter préalablement à l’AGO, dans les délais légau...
Unifiedpost is a niche SaaS player in the e-invoicing and procurement channel space. Regulatory headwinds mean this market is ripe for growth, which should benefit Unifiedpost. Due to some unsuccessful past M&A, the company is in a challenging financial position today. However, it has recently embarked on a divestment path, aiming to streamline the business and improve its fundamentals. We like the new direction, however prefer to take a wait-and-see approach. - ...
Unifiedpost is a niche SaaS player in the e-invoicing and procurement channel space. Regulatory headwinds mean this market is ripe for growth, which should benefit Unifiedpost. Due to some unsuccessful past M&A, the company is in a challenging financial position today. However, it has recently embarked on a divestment path, aiming to streamline the business and improve its fundamentals. We like the new direction, however prefer to take a wait-and-see approach. - ...
>Ex disposals, Q1 results roughly in-line with expectations - Revenues in 24Q1 have fallen to $ 240.4m, down from $ 340m in 23Q1. Net revenues (after voyage expense) in 24Q1 have fallen to $ 203.5m (AAOB $ 197.9m) from $ 305.1m in 23Q1.EBITDA is reported at $ 550.5m but excluding disposal gain of $ 407.6m amounts to $ 142.9m (BB consensus $ 150m), down from $ 258.5m in 23Q1Net profit in 24Q1 has jumped to $ 495.0m (AAOB $ 492.6m) primarily thanks to the $ 40...
AB InBev: Busy BEES. Ahold Delhaize: Small beat, comforting confirmation of 2024 guidance. AMG: 1Q24 better than expected, FY guidance intact, strategic projects on schedule. Bekaert: Soft start to the year with 7% sales miss, FY guidance maintained. Euronav: Transformation at full speed. Marel: Another lacklustre quarter. Montea: 2025 guidance raised, valuations moving into positive territory. SBM Offshore: In-line Q1 trading update. Sif Group: Preview - normal quarter e...
Avis de convocation à l’assemblée générale 2024 des actionnaires ONWARD® et propositions de résolutions EINDHOVEN, Pays-Bas, 03 mai 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext : ONWD), société de technologie médicale à l’origine de thérapies innovantes ciblées sur la restauration du mouvement, de la fonction et de l’indépendance des patients vivant avec une lésion médullaire, annonce ce jour que l’assemblée générale 2024 de ses actionnaires (AG) se tiendra dans la capitale néerlandaise le 13 juin 2024. À cette occasion, la Société soumettra une série de résolutions à délibérati...
Aedifica: First sign of portfolio valuation stabilization. ArcelorMittal: Solid 1Q24 EBITDA beat, softer FCF reflects WC and CAPEX phasing. Belgian telcos: Peer Telenet 1Q24 results, still weak commercial performance. dsm-firmenich AG: Vita-still not-min. IBA: Contract to install a P1 system in Connecticut. KPN: VodafoneZiggo 1Q24 results confirm fixed losses, mobile weaker QoQ. Shell plc: Good start to the year
In this May edition of our Dynamic Top Pick List we replace Arcadis by Fugro. Arcadis continues to deliver consistently on its promises and is working hard to realise its 2026 margin targets via cross selling, leveraging its global engineering platform and numerous self-help measures. In spite of this we remove Arcadis from our Dynamic Top Pick List as the recent & strong share price performance leaves little room for further short term triggers As a service provider to the energy industry, Fu...
IBA signs contract with Yale New Haven Health and Hartford HealthCare to install Proteus®ONE proton therapy solution in Connecticut, US Louvain-La-Neuve, Belgium, 2 May 2024 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces that it has signed a contract with the Connecticut Proton Therapy Center, a collaboration between Yale New Haven Health, Hartford HealthCare and Proton International, for the installation of a Proteus®ONE1 compact proton therapy system. The contract includes a multi-year operation and maintenance agreement,...
IBA signe un contrat avec Yale New Haven Health et Hartford HealthCare pour l’installation d’une solution de protonthérapie Proteus®ONE dans le Connecticut, aux États-Unis Louvain-la-Neuve, Belgique, le 2 mai 2024 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial de la technologie d’accélération de particules, annonce aujourd'hui avoir signé un contrat avec le Connecticut Proton Therapy Center, une collaboration entre Yale New Haven Health, Hartford HealthCare et Proton International, pour l'installation d'un système compact de protonthérapie Proteus®ONE1. Le contrat comprend ...
ONWARD® Medical Convocation of the 2024 Annual General Meeting of Shareholders and Proposed Resolutions EINDHOVEN, the Netherlands, May 02, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today has convened the 2024 Annual General Meeting of Shareholders (AGM), which will include consideration of the resolutions to be submitted for adoption at the AGM, which will be held in Amsterdam, the Netherlands, on ...
• IBA announced the sale of a new ProteusONE system to be installed in Connecticut, US• This is the first system sold in 2024. The first downpayment has been received and the company indicates that the price for a ProteusONE system, with a multi-year maintenance contract, ranges between EUR 40-50m. Margins should reflect the fact that Varian exited the market• We believe that Better-than-expected FY23 results and the improvements foreseen over FY24e will reassure the market and trigger a reratin...
Our trip to South Korea and China revealed Chinese shipbuilders are seeking growth to take on Korea’s established yards who are facing constraints. An eagerness to add capacity is one of our takeaways, as well as a gloomy outlook for Chinese real estate, which in our view should inevitably weigh on dry bulk demand.
ONWARD® Medical annonce ses résultats financiers et opérationnels pour l’exercice 2023 et partage les faits qui ont marqué l’exercice 2024 à ce jour Dépôt auprès de la FDA d’une demande de classification du dispositif ARC-EX® System basée sur les risques (demande « De Novo ») Levée de fonds de 20 millions d’euros Annonce des résultats préliminaires positifs de l’étude pivot Up-LIFT Mise en place d’un partenariat visant à accéder rapidement à la Veterans Health Administration des États-Unis Poursuite de la mise au point de thérapies avec interface cerveau-ordinateur pour les lésions médu...
Onward reported its FY23 results, and confirmed its FY24 outlook and key milestones. 2024 is set to become the year of its first launch, with ARCEX approval expected 2H24. Meanwhile, the pivotal trial in blood pressure control with ARCIM remains planned to start 2H24. YE23 cash landed at € 29.8m and was complemented with a € 20m equity raise to deliver cash runway into mid-2025. We reiterate our Buy rating and € 9.3 TP.
ONWARD® Medical Reports Full Year 2023 Financial and Operating Results and Shares 2024 Highlights Year-to-Date Submitted FDA De Novo application for ARC-EX® System Successfully raised EUR 20M in equity capital Announced positive top-line results from Up-LIFT pivotal study Forged partnership to provide rapid access to US Veterans Health Administration Continued to pioneer brain-computer interface therapies for SCI EINDHOVEN, The Netherlands, April 25, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.